A Pilot Phase 1/2, Double Blind, Parallel Group, Controlled Study of the Safety, Tolerability and preliminary Efficacy evaluation of intravitreally administered Pfenex ranibizumab (PF582) biosimilar versus Lucentis (registered trademark) for the treatment of neovascular age related macular degeneration (AMD)
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Sponsors Pelican Expression Technology; Pfenex
- 08 Aug 2016 Results published in the Pfenex Media Release
- 09 May 2016 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016.